Clinical study: Myocardial infarction
Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction

https://doi.org/10.1016/S0735-1097(02)01804-1Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

The aim of this study was to determine the prognostic value of right ventricular (RV) function in patients after a myocardial infarction (MI).

Background

Right ventricular function has been shown to predict exercise capacity, autonomic imbalance and survival in patients with advanced heart failure (HF).

Methods

Two-dimensional echocardiograms were obtained in 416 patients with left ventricular (LV) dysfunction (ejection fraction [LVEF] ≤40%) from the Survival And Ventricular Enlargement (SAVE) echocardiographic substudy (mean 11.1 ± 3.2 days post infarction). Right ventricular function from the apical four-chamber view, assessed as the percent change in the cavity area from end diastole to end systole (fractional area change [FAC]), was related to clinical outcome.

Results

Right ventricular function correlated only weakly with the LVEF (r = 0.12, p = 0.013). On univariate analyses, the RV FAC was a predictor of mortality, cardiovascular mortality and HF (p < 0.0001 for all) but not recurrent MI. After adjusting for age, gender, diabetes mellitus, hypertension, previous MI, LVEF, infarct size, cigarette smoking and treatment assignment, RV function remained an independent predictor of total mortality, cardiovascular mortality and HF. Each 5% decrease in the RV FAC was associated with a 16% increased odds of cardiovascular mortality (95% confidence interval 4.3% to 29.2%; p = 0.006).

Conclusions

Right ventricular function is an independent predictor of death and the development of HF in patients with LV dysfunction after MI.

Abbreviations

FAC
fractional area change
HF
heart failure
LV
left ventricle or ventricular
LVEF
ejection fraction
MI
myocardial infarction
RV
right ventricle or ventricular
SAVE
Survival And Ventricular Enlargement trial

Cited by (0)

Dr. Zornoff is a recipient of a scholarship (no. 99/04954-0) from the Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp), Brazil. The SAVE study was originally supported by Squibb Inc.